Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease

Documenti analoghi

• A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States
  di: Nikita Mittal, et al.
  Pubblicazione: (2024)
• Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2024)
• Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2024)
• The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
  di: Lana Bridi, et al.
  Pubblicazione: (2024)
• Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2025)